

# NANO KOREA 2020

## July 1~3, KINTEX, Korea

---

### Dan Peer, Ph.D.

Director, Laboratory of Precision NanoMedicine, Tel Aviv University

**Address:**

**Telephone:** +972-3640-7925

**Fax:** +972-3640-5926

**E-mail:** peer@tauex.tau.ac.il

**Nationality:** Israeli

**Web:** <http://dan-peer.tau.ac.il>

---

### **EDUCATION**

Tel Aviv University, Tel Aviv, Israel	Ph.D.	Biophysics	<b>2004</b>
MIT (Robert S. Langer Lab)		Internship	<b>2003</b>
University of Cambridge, Cambridge, UK (Cesar Milstein Lab)			<b>2000</b>
Tel Aviv University, Tel Aviv, Israel	MS	Biochemistry	<b>1999</b>
Tel Aviv University, Tel Aviv, Israel	BS	Biology	<b>1997</b>

### **PROFESSIONAL ACTIVITIES**

2005 - 2008: Research Fellow: Immune Disease Institute, Harvard Medical School, Boston, MA, USA

2008 - 2011: Assistant Professor; Director, Laboratory of NanoMedicine, Tel Aviv University.

2011 - Visiting Professor, Molecular Medicine, Harvard Medical School

2011 - Full affiliated Member, Methodist Hospital Research Institute, Houston, TX, USA.

2011 - 2015: Tenured Associate Professor, and Director, Laboratory of NanoMedicine, Tel Aviv University, Israel

2015 - Full Professor and Director, Laboratory of NanoMedicine, Tel Aviv University, Tel Aviv,

2012 - 2017: Managing Director, Israel National Nanomedicine consortium.

2016 - Chair, Cancer Biology Research Center (CBRC), Tel Aviv University

2017 - Founding and Managing Director, SPARK Tel Aviv, Center for Translational Medicine, Tel Aviv University.

2019 - 2020 : Vice Dean for Research, George S. Wise Faculty of Life Sciences, Tel Aviv University.

2020 - Incoming Vice President for Research and Development, Tel Aviv University

### **AWARD AND HONORS**

2009: Marie Curie Fellow, European Union.

2010: Innovator Award: Kenneth Rainin Foundation, Oakland, CA, USA

2011: Breakthrough Award: Kenneth Rainin Foundation, Oakland, CA, USA

2013: Breakthrough Award: Kenneth Rainin Foundation, Oakland, CA, USA

2014: Elected Member, Israel Young Academy of Science.

2014: Innovator Award, Untold News Award, NYC, NY, USA.

2014 - 2016: President, Israeli Chapter of the Controlled Release Society.

2015: 1<sup>st</sup> recipient of the UK-Israel Professorship (Oxford University)

2017: Nanos Award - World Leader Award for substantial contributions to the field of NanoMedicine, CLINAM 10<sup>th</sup> Conference, Basel, Switzerland.

# NANO KOREA 2020

## July 1~3, KINTEX, Korea

### **MAIN SCIENTIFIC PUBLICATION**

1. **Peer D**, Zhu P, Carman CV, Lieberman J and Shimaoka M (2007). Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl. Acad. Sci. USA, 150, 4095-4100.
2. **Peer D.\***, Karp JM\*, Hong S\*, Farokhzad O, Margalit R, and Langer R (2007). Nanocarriers as emerging platforms for cancer therapy. Nature Nanotechnology 2,751-760.
3. **Peer D.**, Park EJ, Morishita Y, Carman CV, and Shimaoka M (2008). Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammation Target. Science. 319, 627-630.
4. Kedmi R, Ben-Arie N, and **Peer D** (2010). The systemic toxicity of positively charged lipid-nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials,31, 6867-6.
5. Moyano D., Goldsmith M., Solfiell D., Landesman-Milo D., Miranda O., **Peer D.\*** and Rotello VM\* (2012). Hydrophobicity Dictates Immune response. Journal of American Chemical Society 134(9), 3965-3967.
6. Cohen K., Emmanuel R., Kisin-Finfer E., Shabat D., and **Peer D** (2014). Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. ACS Nano. 8 (3), 2183-2195
7. Cohen Z.R., Ramisetty S., Peshes-Yaloz N., Goldsmith M., Vol A., Zibly Z. and **Peer D** (2015). Localized RNAi Therapeutics of Chemo-Resistant Grade IV Glioma using Hyaluronan-Grafted Lipid-based Nanoparticles. ACS Nano. 9(2), 1581-1591.
8. Ramishetti S, Kedmi R, Goldsmith M, Leonard F, Speague AG, Godin B, Gozin M, Cullis P, Dykxhoorn DM, and **Peer D**. (2015). Systemic Gene Silencing in Primary T lymphocytes using Targeted Lipid Nanoparticles. ACS Nano 9(7):6706-16.
9. Weinstein S., Toker I.A., Emmanuel R., Ramishetti S., Hazan-Halevy I., Rosenblum D., Goldsmith M., Abraham A., Benjamini O., Bairey O., Raanani P., Nagler A., Lieberman J. and **Peer D** (2016). Harnessing RNAi based-Nanomedicines for Therapeutic Gene Silencing in B Cell Malignancies. Proc. Natl. Acad. Sci. USA 113 (1), E17-25.
10. Kedmi R. and **Peer D** (2016). Zooming in on selectins in Cancer. SCIENCE Translational Med. 8, 345fs11.
11. Mizrahy S, Hazan-Halevy I, Dammes N, Landesman-Milo D, and Peer D (2017). Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes. Molecular Therapy 25(7):1491-1500.
12. Kedmi R., Viaga N. Ramishetti S, Goldsmith M, Rosenblum D, Dammes N, Hazan-Halevy I, Nahary L, Leviatan-Ben-Arye S, Harlev M, Behlke M, Benhar I, Lieberman J, and **Peer D** (2018). A modular platform for targeted RNAi therapeutics. Nature Nanotechnology. 13(3):214-219. A novel universal platform for RNAi therapeutics.
13. Rosenblum D., Joshi N., Tao W., Karp M.\* , and **Peer D\***. (2018). Progress and Challenges Towards Targeted Delivery of Cancer Therapeutics. Nature Communications Apr 12;9(1):1410. doi: 10.1038/s41467-018-03705-y.
14. Veiga N., Goldsmith M., Granot Y., Rosenblum D., Dammes N., Kedmi R., Ramishetti S., and **Peer D** (2018). Cell Specific Delivery of Modified mRNA Expressing Therapeutic Proteins to Leukocytes. Nature Communications 9(1):4493. doi: 10.1038/s41467-018-06936-1. The first, cell specific targeting of mRNA.

### **RESEARCH INTERESTS**

RNA Therapeutics, targeted nanoparticles, mAbs.